SCHEMBL5122007

SCHEMBL5122007

Cc1ccc(C2=NOC3(CCN(C(=O)Nc4ccccc4Cl)CC3)C2)cc1

nearest known ligand 0.50

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
TRPM8 Q7Z2W7 1/20 0.48
GAA P10253 2/20 0.44
TSHR P16473 1/20 0.44
KMT2A Q03164 2/20 0.44
ALDH1A1 P00352 3/20 0.43
KDM4E B2RXH2 2/20 0.43
HPGD P15428 2/20 0.43
FAAH O00519 2/20 0.43
SMO Q99835 3/20 0.43
MEN1 O00255 1/20 0.43
L3MBTL1 Q9Y468 1/20 0.43
DGAT1 O75907 1/20 0.43
TAS1R3 Q7RTX0 1/20 0.43
TAS1R1 Q7RTX1 1/20 0.43
TAS1R2 Q8TE23 1/20 0.43
TP53 P04637 2/20 0.42
MAPT P10636 2/20 0.42
LMNA P02545 1/20 0.42
NPY5R Q15761 1/20 0.42
HTT P42858 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5119717 0.92 NPY5R (0.46) GAATSHRALDH1A1KDM4EHPGD
SCHEMBL5124880 0.92 FAAH (0.49) ALDH1A1KDM4EHPGDFAAHSMO
SCHEMBL5129689 0.90 KMT2A (0.47) GAAKMT2AFAAHLMNA
SCHEMBL5125820 0.89 ALDH1A1 (0.45) TRPM8GAATSHRALDH1A1KDM4E
SCHEMBL5124361 0.88 KMT2A (0.47) TRPM8KMT2ADGAT1MAPTLMNA
SCHEMBL5119673 0.88 KMT2A (0.44) KMT2AKDM4EFAAHTP53MAPT
SCHEMBL5125133 0.87 TRPM8 (0.52) TRPM8ALDH1A1KDM4EHPGDFAAH
SCHEMBL5117764 0.87 FAAH (0.43) TRPM8TSHRKMT2AKDM4EHPGD
SCHEMBL5129887 0.87 KMT2A (0.45) KMT2AALDH1A1MEN1MAPT
SCHEMBL5130783 0.86 PKM (0.53) TSHRKMT2AALDH1A1KDM4EFAAH

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1888596-B1 SUBSTITUTED SPIRO COMPOUNDS AND THEIR USE FOR PRODUCING PAIN-RELIEF MEDICAMENTS GRUENENTHAL GMBH (DE) 2014-10-22 EP claimed
US-8772307-B2 Substituted spiro compounds and their use for producing pain-relief medicaments GRUENENTHAL GMBH (DE) 2014-07-08 US claimed
US-20080269271-A1 Analgesics; antidepressants; neurodegenerative diseases; antiepileptic agents; cognition activators; antitussive agents; incotinence; irritable bowel syndrome; stroke; vision defects; antiinflammatory agents; skin disorders; diarrhea; eating disorders GRUENENTHAL GMBH (DE) 2008-10-30 US claimed
US-20080269271-A1 Analgesics; antidepressants; neurodegenerative diseases; antiepileptic agents; cognition activators; antitussive agents; incotinence; irritable bowel syndrome; stroke; vision defects; antiinflammatory agents; skin disorders; diarrhea; eating disorders GRUENENTHAL GMBH (DE) 2008-10-30 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080269271-A1 Analgesics; antidepressants; neurodegenerative diseases; antiepileptic agents; cognition activators; antitussive agents; incotinence; irritable bowel syndrome; stroke; vision defects; antiinflammatory agents; skin disorders; diarrhea; eating disorders INA, SCN1A, SI TRPM8 426/4885GAA 1077/4885TSHR 3033/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.